Luo, H., Li, T., Meng, F., Hong, Z., Cao, Y., Wang, G., . . . Zhou, X. CAR T-cell therapy for relapsed/refractory CD5-positive diffuse large B-cell lymphoma yields more favorable outcomes than standard therapy. China Anti-Cancer Association.
Chicago Style (17th ed.) CitationLuo, Hui, Tongjuan Li, Fankai Meng, Zhenya Hong, Yang Cao, Gaoxiang Wang, Liang Huang, and Xiaoxi Zhou. CAR T-cell Therapy for Relapsed/refractory CD5-positive Diffuse Large B-cell Lymphoma Yields More Favorable Outcomes than Standard Therapy. China Anti-Cancer Association.
MLA (9th ed.) CitationLuo, Hui, et al. CAR T-cell Therapy for Relapsed/refractory CD5-positive Diffuse Large B-cell Lymphoma Yields More Favorable Outcomes than Standard Therapy. China Anti-Cancer Association.
Warning: These citations may not always be 100% accurate.